Abstract “Financial toxicity” has now become a familiar term used in the discussion of cancer
drugs, and it is gaining traction in the literature given the high price of newer classes of …

Importance The increasing cost of prescription drugs in the United States has become a
source of concern for patients, prescribers, payers, and policy makers. Objectives To review …

In this report, the authors provide comprehensive and up‐to‐date US data on disparities in
cancer occurrence, major risk factors, and access to and utilization of preventive measures …

Importance A common justification for high cancer drug prices is the sizable research and
development (R&D) outlay necessary to bring a drug to the US market. A recent estimate of …

Financial toxicity is the adverse impact of a cancer diagnosis on a patient's financial well‐
being resulting from direct or indirect costs. Potential consequences of financial toxicity …

Globally, annual spending on anticancer drugs is around US $100 billion, and is predicted
to rise to $150 billion by 2020. In the USA, a novel anticancer drug routinely costs more than …

Evidence suggests that a considerably large proportion of cancer patients are affected by
treatment-related financial harm. As medical debt grows for some with cancer, the …

PURPOSE Clinical trial evidence is routinely evaluated for initial drug approvals, yet the
benefit of indication extensions remains uncertain. This study evaluates the clinical benefit …

Increasing cancer drug prices present global challenges to treatment access and cancer
outcomes. Substantial variability exists in drug pricing across countries. In countries without …

Importance Both novel and next-in-class cancer drugs have a role in oncology, but the
relative development of each is understudied. Objective To characterize the mechanisms of …